About the Study: In a comparative study of 11,681 US cancer clinical trial, industry-sponsored trials were more likely to focus on single-agent drug therapies, while federally sponsored trials were more likely to evaluate nontreatment interventions, multimodality treatment strategies, deescalation approaches, and therapies for rare cancers and children.
JAMA+ Trials
Explore JAMA+ Trials for editor-curated JAMA Network clinical trials, commentary, multimedia, and more, led by Editor in Chief Alison Huang, MD, MAS.
Journalists may find Dr Huang's email newsletter, JAMA+ Trials "Theme of the Month," and the JAMA+ Trials search page helpful in reporting.
Corresponding Author: Joseph M. Unger, PhD, SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3-C102, PO Box 19024, Seattle, WA 98109-1024 (junger@fredhutch.org).
10.1001/jamaoncol.2026.3026
To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Editor's Note: Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Journal
JAMA Oncology